
Pfizer Inc.(PFE)- Would PFE growth be constant after vaccine boom ends?
in Company Report , Healthcare & Life Sciences , Pharma & Biotech on August 23, 2022This report is useful for M&A and business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for insights on any specific sector/industry and market recommendations.
Pfizer Inc.(PFE)
Pfizer is well positioned to increase its revenue by $25bn by the end of 2020. The series of acquisition made by the company in the last two years is expected to contribute towards the revenue in the coming years.
Highlights
Valuation
– Enterprise Value
– CrispIdea Forecast
– CrispIdea Segment Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum
Actual & Historical Performance
– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Developments
– M&A Deals
Peer Performance
– Summary
– Profitability
– Growth
– Price Performance
Ownership
Stock Price Performance
Crispidea Coverage
No of Pages : 37